STOCK TITAN

[SCHEDULE 13G] SOPHiA GENETICS SA SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Schedule 13G filing: On 27 June 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC jointly filed a Schedule 13G reporting a beneficial position in SOPHiA GENETICS SA (CUSIP H82027105).

The reporting persons collectively hold 3,719,140 ordinary shares, representing 5.6 % of the outstanding class. All voting and dispositive authority over the shares is shared; each entity reports zero sole voting or dispositive power and full shared power over the entire stake, triggering the 5 % disclosure threshold under Section 13(d).

ACM is organized in Delaware and operates as an investment adviser, while Braddock Partners Offshore, LP is a Cayman Islands limited partnership and Braddock Capital Offshore, LLC is a Delaware limited-liability company. The certification states that the securities were acquired ‘not for the purpose of or with the effect of changing or influencing the control’ of the issuer. No additional group members, subsidiary acquisitions, or 5 %-or-less disclaimers are indicated. An Exhibit A Joint Filing Agreement accompanies the submission.

Deposito Schedule 13G: Il 27 giugno 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP e Braddock Capital Offshore, LLC hanno presentato congiuntamente un Schedule 13G riportando una posizione beneficiaria in SOPHiA GENETICS SA (CUSIP H82027105).

Le persone segnalanti detengono collettivamente 3.719.140 azioni ordinarie, rappresentando il 5,6% della classe in circolazione. Tutta l'autorità di voto e dispositiva sulle azioni è condivisa; ciascuna entità dichiara di non avere poteri di voto o dispositivi esclusivi, ma pieno potere condiviso sull'intera partecipazione, superando così la soglia di divulgazione del 5% ai sensi della Sezione 13(d).

ACM è costituita nel Delaware e opera come consulente di investimento, mentre Braddock Partners Offshore, LP è una società in accomandita delle Isole Cayman e Braddock Capital Offshore, LLC è una società a responsabilità limitata del Delaware. La certificazione afferma che i titoli sono stati acquisiti «non allo scopo di modificare o influenzare il controllo» dell'emittente. Non sono indicati altri membri del gruppo, acquisizioni di sussidiarie o dichiarazioni di esclusione per partecipazioni pari o inferiori al 5%. Alla presentazione è allegato un Accordo Congiunto di Deposito (Exhibit A).

Presentación Schedule 13G: El 27 de junio de 2025, Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP y Braddock Capital Offshore, LLC presentaron conjuntamente un Schedule 13G reportando una posición beneficiaria en SOPHiA GENETICS SA (CUSIP H82027105).

Las personas que reportan poseen colectivamente 3.719.140 acciones ordinarias, representando el 5,6% de la clase en circulación. Toda la autoridad de voto y disposición sobre las acciones es compartida; cada entidad reporta cero poder exclusivo de voto o disposición y pleno poder compartido sobre toda la participación, superando así el umbral de divulgación del 5% según la Sección 13(d).

ACM está organizada en Delaware y opera como asesor de inversiones, mientras que Braddock Partners Offshore, LP es una sociedad limitada de las Islas Caimán y Braddock Capital Offshore, LLC es una sociedad de responsabilidad limitada de Delaware. La certificación indica que los valores fueron adquiridos «no con el propósito ni con el efecto de cambiar o influir en el control» del emisor. No se indican miembros adicionales del grupo, adquisiciones subsidiarias ni exenciones para participaciones iguales o inferiores al 5%. Se adjunta un Acuerdo Conjunto de Presentación (Exhibit A) con la presentación.

Schedule 13G 제출: 2025년 6월 27일 Akre Capital Management, LLC(ACM), Braddock Partners Offshore, LP 및 Braddock Capital Offshore, LLC가 공동으로 SOPHiA GENETICS SA(CUSIP H82027105)에 대한 실질적 보유 지분을 보고하는 Schedule 13G를 제출했습니다.

보고자들은 총 3,719,140 보통주를 보유하고 있으며, 이는 발행 주식의 5.6%에 해당합니다. 모든 의결권 및 처분 권한은 공유되며, 각 기관은 단독 의결권 또는 처분 권한이 없고 전체 지분에 대한 전면적인 공유 권한을 보고하여 섹션 13(d)에 따른 5% 공시 기준을 충족합니다.

ACM은 델라웨어에 설립된 투자 자문사이며, Braddock Partners Offshore, LP는 케이맨 제도 유한책임조합, Braddock Capital Offshore, LLC는 델라웨어 유한책임회사입니다. 인증서에는 증권이 ‘발행자의 지배권 변경 또는 영향’을 목적으로 하지 않고 취득되었음이 명시되어 있습니다. 추가 그룹 구성원, 자회사 인수 또는 5% 이하 면책 조항은 없습니다. 제출서류에는 Exhibit A 공동 제출 계약서가 포함되어 있습니다.

Dépôt du Schedule 13G : Le 27 juin 2025, Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP et Braddock Capital Offshore, LLC ont conjointement déposé un Schedule 13G déclarant une position bénéficiaire dans SOPHiA GENETICS SA (CUSIP H82027105).

Les personnes déclarantes détiennent collectivement 3 719 140 actions ordinaires, représentant 5,6 % de la classe en circulation. Tous les droits de vote et de disposition sur les actions sont partagés ; chaque entité déclare ne détenir aucun pouvoir de vote ou de disposition exclusif, mais un pouvoir partagé total sur l’intégralité de la participation, dépassant ainsi le seuil de divulgation de 5 % conformément à la Section 13(d).

ACM est organisée dans le Delaware et exerce en tant que conseiller en investissement, tandis que Braddock Partners Offshore, LP est une société en commandite des îles Caïmans et Braddock Capital Offshore, LLC une société à responsabilité limitée du Delaware. La certification indique que les titres ont été acquis « non dans le but ou dans l’effet de changer ou d’influencer le contrôle » de l’émetteur. Aucun autre membre du groupe, acquisition de filiales ou clause de non-responsabilité pour des participations de 5 % ou moins n’est indiqué. Un accord conjoint de dépôt (Exhibit A) accompagne la soumission.

Schedule 13G Einreichung: Am 27. Juni 2025 reichten Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP und Braddock Capital Offshore, LLC gemeinsam ein Schedule 13G ein, das eine wirtschaftliche Beteiligung an SOPHiA GENETICS SA (CUSIP H82027105) meldet.

Die meldenden Personen halten zusammen 3.719.140 Stammaktien, was 5,6 % der ausstehenden Aktienklasse entspricht. Alle Stimm- und Verfügungsrechte an den Aktien werden gemeinsam ausgeübt; jede Einheit meldet keine alleinigen Stimm- oder Verfügungsrechte, sondern volle gemeinsame Rechte an der gesamten Beteiligung, wodurch die Offenlegungsschwelle von 5 % gemäß Abschnitt 13(d) ausgelöst wird.

ACM ist in Delaware organisiert und fungiert als Investmentberater, während Braddock Partners Offshore, LP eine Limited Partnership auf den Cayman Islands ist und Braddock Capital Offshore, LLC eine Delaware Limited Liability Company. Die Bescheinigung besagt, dass die Wertpapiere „nicht zum Zweck oder mit der Absicht erworben wurden, die Kontrolle“ des Emittenten zu ändern oder zu beeinflussen. Es sind keine weiteren Gruppenmitglieder, Tochtergesellschaftserwerbe oder 5-%-oder-weniger-Ausschlüsse angegeben. Der Einreichung liegt eine Exhibit A Joint Filing Agreement bei.

Positive
  • Akre Capital Management and its affiliates have accumulated 3.72 million shares (5.6 %) of SOPHiA GENETICS, confirming meaningful institutional ownership.
Negative
  • None.

Insights

Akre-led group reveals 5.6 % SOPH stake; disclosure appears strategically passive.

The filing confirms that ACM and related offshore vehicles now control 3.72 million SOPHiA GENETICS shares. The stake crosses the 5 % threshold but remains far from a controlling level, and the certification expressly disclaims any intent to influence control. Because voting and dispositive power are shared and no additional action is signalled, the market impact is likely limited to heightened institutional visibility. Investors may view the involvement of a professional investment adviser positively, yet the passive nature of the filing provides no direct insight into near-term operating performance or strategic change.

Passive 13G indicates institutional ownership with no governance change expected.

This Schedule 13G is a routine disclosure of a >5 % holding by three related entities under common management. The absence of sole voting power and the explicit statement that the securities are not held to influence control suggest a purely passive investment. From a governance perspective, the issuer’s board and existing shareholders face no immediate threat of activism. Nonetheless, a single group now controls a non-trivial block, which could become influential in future governance votes should their intentions evolve, but nothing in the filing indicates such a plan.

Deposito Schedule 13G: Il 27 giugno 2025 Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP e Braddock Capital Offshore, LLC hanno presentato congiuntamente un Schedule 13G riportando una posizione beneficiaria in SOPHiA GENETICS SA (CUSIP H82027105).

Le persone segnalanti detengono collettivamente 3.719.140 azioni ordinarie, rappresentando il 5,6% della classe in circolazione. Tutta l'autorità di voto e dispositiva sulle azioni è condivisa; ciascuna entità dichiara di non avere poteri di voto o dispositivi esclusivi, ma pieno potere condiviso sull'intera partecipazione, superando così la soglia di divulgazione del 5% ai sensi della Sezione 13(d).

ACM è costituita nel Delaware e opera come consulente di investimento, mentre Braddock Partners Offshore, LP è una società in accomandita delle Isole Cayman e Braddock Capital Offshore, LLC è una società a responsabilità limitata del Delaware. La certificazione afferma che i titoli sono stati acquisiti «non allo scopo di modificare o influenzare il controllo» dell'emittente. Non sono indicati altri membri del gruppo, acquisizioni di sussidiarie o dichiarazioni di esclusione per partecipazioni pari o inferiori al 5%. Alla presentazione è allegato un Accordo Congiunto di Deposito (Exhibit A).

Presentación Schedule 13G: El 27 de junio de 2025, Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP y Braddock Capital Offshore, LLC presentaron conjuntamente un Schedule 13G reportando una posición beneficiaria en SOPHiA GENETICS SA (CUSIP H82027105).

Las personas que reportan poseen colectivamente 3.719.140 acciones ordinarias, representando el 5,6% de la clase en circulación. Toda la autoridad de voto y disposición sobre las acciones es compartida; cada entidad reporta cero poder exclusivo de voto o disposición y pleno poder compartido sobre toda la participación, superando así el umbral de divulgación del 5% según la Sección 13(d).

ACM está organizada en Delaware y opera como asesor de inversiones, mientras que Braddock Partners Offshore, LP es una sociedad limitada de las Islas Caimán y Braddock Capital Offshore, LLC es una sociedad de responsabilidad limitada de Delaware. La certificación indica que los valores fueron adquiridos «no con el propósito ni con el efecto de cambiar o influir en el control» del emisor. No se indican miembros adicionales del grupo, adquisiciones subsidiarias ni exenciones para participaciones iguales o inferiores al 5%. Se adjunta un Acuerdo Conjunto de Presentación (Exhibit A) con la presentación.

Schedule 13G 제출: 2025년 6월 27일 Akre Capital Management, LLC(ACM), Braddock Partners Offshore, LP 및 Braddock Capital Offshore, LLC가 공동으로 SOPHiA GENETICS SA(CUSIP H82027105)에 대한 실질적 보유 지분을 보고하는 Schedule 13G를 제출했습니다.

보고자들은 총 3,719,140 보통주를 보유하고 있으며, 이는 발행 주식의 5.6%에 해당합니다. 모든 의결권 및 처분 권한은 공유되며, 각 기관은 단독 의결권 또는 처분 권한이 없고 전체 지분에 대한 전면적인 공유 권한을 보고하여 섹션 13(d)에 따른 5% 공시 기준을 충족합니다.

ACM은 델라웨어에 설립된 투자 자문사이며, Braddock Partners Offshore, LP는 케이맨 제도 유한책임조합, Braddock Capital Offshore, LLC는 델라웨어 유한책임회사입니다. 인증서에는 증권이 ‘발행자의 지배권 변경 또는 영향’을 목적으로 하지 않고 취득되었음이 명시되어 있습니다. 추가 그룹 구성원, 자회사 인수 또는 5% 이하 면책 조항은 없습니다. 제출서류에는 Exhibit A 공동 제출 계약서가 포함되어 있습니다.

Dépôt du Schedule 13G : Le 27 juin 2025, Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP et Braddock Capital Offshore, LLC ont conjointement déposé un Schedule 13G déclarant une position bénéficiaire dans SOPHiA GENETICS SA (CUSIP H82027105).

Les personnes déclarantes détiennent collectivement 3 719 140 actions ordinaires, représentant 5,6 % de la classe en circulation. Tous les droits de vote et de disposition sur les actions sont partagés ; chaque entité déclare ne détenir aucun pouvoir de vote ou de disposition exclusif, mais un pouvoir partagé total sur l’intégralité de la participation, dépassant ainsi le seuil de divulgation de 5 % conformément à la Section 13(d).

ACM est organisée dans le Delaware et exerce en tant que conseiller en investissement, tandis que Braddock Partners Offshore, LP est une société en commandite des îles Caïmans et Braddock Capital Offshore, LLC une société à responsabilité limitée du Delaware. La certification indique que les titres ont été acquis « non dans le but ou dans l’effet de changer ou d’influencer le contrôle » de l’émetteur. Aucun autre membre du groupe, acquisition de filiales ou clause de non-responsabilité pour des participations de 5 % ou moins n’est indiqué. Un accord conjoint de dépôt (Exhibit A) accompagne la soumission.

Schedule 13G Einreichung: Am 27. Juni 2025 reichten Akre Capital Management, LLC (ACM), Braddock Partners Offshore, LP und Braddock Capital Offshore, LLC gemeinsam ein Schedule 13G ein, das eine wirtschaftliche Beteiligung an SOPHiA GENETICS SA (CUSIP H82027105) meldet.

Die meldenden Personen halten zusammen 3.719.140 Stammaktien, was 5,6 % der ausstehenden Aktienklasse entspricht. Alle Stimm- und Verfügungsrechte an den Aktien werden gemeinsam ausgeübt; jede Einheit meldet keine alleinigen Stimm- oder Verfügungsrechte, sondern volle gemeinsame Rechte an der gesamten Beteiligung, wodurch die Offenlegungsschwelle von 5 % gemäß Abschnitt 13(d) ausgelöst wird.

ACM ist in Delaware organisiert und fungiert als Investmentberater, während Braddock Partners Offshore, LP eine Limited Partnership auf den Cayman Islands ist und Braddock Capital Offshore, LLC eine Delaware Limited Liability Company. Die Bescheinigung besagt, dass die Wertpapiere „nicht zum Zweck oder mit der Absicht erworben wurden, die Kontrolle“ des Emittenten zu ändern oder zu beeinflussen. Es sind keine weiteren Gruppenmitglieder, Tochtergesellschaftserwerbe oder 5-%-oder-weniger-Ausschlüsse angegeben. Der Einreichung liegt eine Exhibit A Joint Filing Agreement bei.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



AKRE CAPITAL MANAGEMENT, LLC
Signature:By: /s/ Charles T. Akre, Jr.*
Name/Title:Charles T. Akre, Jr./Managing Member
Date:06/27/2025
Braddock Partners Offshore, LP
Signature:By: Braddock Capital Offshore, LLC, its general partner, By: /s/ Charles T. Akre, Jr.*
Name/Title:Charles T. Akre, Jr./Managing Member
Date:06/27/2025
Braddock Capital Offshore, LLC
Signature:By: /s/ Charles T. Akre, Jr.*
Name/Title:Charles T. Akre, Jr./Managing Member
Date:06/27/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Exhibit Information

Exhibit A - Joint Filing Agreement

FAQ

Who filed the Schedule 13G for SOPHiA GENETICS (SOPH) dated 27 June 2025?

The filing was made jointly by Akre Capital Management, LLC, Braddock Partners Offshore, LP, and Braddock Capital Offshore, LLC.

How many SOPHiA GENETICS shares are reported in the filing?

The reporting persons beneficially own 3,719,140 ordinary shares.

What percentage of SOPHiA GENETICS’ outstanding shares does this represent?

The disclosed stake equals 5.6 % of the outstanding class.

Do the reporting persons have sole or shared voting power over these shares?

They report 0 shares with sole voting power and 3,719,140 shares with shared voting power.

What is the event date that triggered the Schedule 13G filing?

The triggering event occurred on 20 June 2025.

Where is SOPHiA GENETICS’ principal executive office located?

The company’s principal office is at 401 Park Drive Suite 505, Boston, MA 02215, USA.
Sophia Genetics Sa

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Latest SEC Filings

SOPH Stock Data

203.81M
62.47M
6.53%
54.32%
0.09%
Health Information Services
Healthcare
Link
Switzerland
Rolle